The patented NuGenerex Immuno-Oncology (Formerly A
Post# of 36537
(Total Views: 563)
Posted On: 08/16/2020 10:17:04 PM
The patented NuGenerex Immuno-Oncology (Formerly Antigen Express) Ii-Key technology uses synthetic peptides that mimic essential protein regions from a virus that are chemically linked to the 4-amino acid Ii-Key to ensure robust immune system activation. In particular , the Ii-Key ensures potent activation of CD4+ T cells , which in turn facilitates antibody production to ward off infection. This Ii-Key modification can be applied to any protein fragment of any pathogen to increase the potency of immune stimulation.
Another article on T cells....GNBT's vaccine activates T cells!
https://norwalkreflector.com/news/271953/why-...new-study/
The findings also offer new insights that could help in developing a vaccine by looking at T cells, which help fight the virus.
Currently, all major candidates for a coronavirus vaccine undergoing clinical trials focus on harnessing a single antibody protein that can neutralize the virus
Another article on T cells....GNBT's vaccine activates T cells!
https://norwalkreflector.com/news/271953/why-...new-study/
The findings also offer new insights that could help in developing a vaccine by looking at T cells, which help fight the virus.
Currently, all major candidates for a coronavirus vaccine undergoing clinical trials focus on harnessing a single antibody protein that can neutralize the virus
(3)
(0)Generex Biotechnology Corp. (GNBTQ) Stock Research Links
Scroll down for more posts ▼